UNSPSC 51421702: Corticorelin

This classification denotes a crh gene with the molecular formula C208H344N60O63S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 305OE8862Y, chemically known as l-alaninamide, l-seryl-l-glutaminyl-l-alpha-glutamyl-l-prolyl-l-prolyl-l-isoleucyl-l-seryl-l-leucyl-l-alpha-aspartyl-l-leucyl-l-threonyl-l-phenylalanyl-l-histidyl-l-leucyl-l-leucyl-l-arginyl-l-alpha-glutamyl-l-valyl-l-leucyl-l-alpha-glutamyl-l-methionyl-l-thronyl-l-lysyl-l-alanyl-l-alpha-aspartyl-l-glutaminyl-l-leucyl-l-alanyl-l-glutaminyl-l-glutaminyl-l-alanyl-l-histidyl-l-seryl-l-asparaginyl-l-arginyl-l-lysyl-l-leucyl-l-leucyl-l-alpha-aspartyl-l-isoleucyl- but generally known as corticorelin, which bears US NIH Compound Identifier 16132344.

UNSPSC 51421702 Corticorelin is a Commodity code that in recent state and local procurement appears to span pharmaceutical products and prescription-related services well beyond its nominal scope. The recent opportunities tagged to this code—a Seminole County, Florida procurement for naloxone and drug deactivation systems, and a Texas Health and Human Services Commission request for information on direct-to-manufacturer prescription programs—suggest significant scope drift between the code's name and what state and local bodies are actually buying. State and local issuing bodies soliciting under this code include county health departments and state health and human services agencies; the mix is limited in the available record but extends across health-focused jurisdictions with both operational procurement (naloxone supplies) and strategic pharmacy program development (direct contracting capability assessment).

The recent activity spans Florida and Texas, with Seminole County issuing a competitive IFB (IFB60459723LAS, due July 26, 2023) for annual procurement of 1,900 units of naloxone and 800 drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building, and the Texas HHS Commission issuing an RFI (HHS0017013, closed April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription fulfillment and negotiated pricing models for self-insured plans and state employees. The code shows thin recent activity and apparent misalignment between its nominal pharmaceutical indication and the health systems procurement and pharmacy benefit infrastructure work actually tagged to it—a signal that this code may see limited relevant opportunity volume or that state and local procurement offices are applying it inconsistently to health-sector purchases.